Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-7 Japan registry entry in relapsed/refractory multiple myeloma
jRCT2011210001Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of belantamab mafodotin, daratumumab, bortezomib and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by GSK. Primary endpoint: Progression-free survival. Started Jul 2021; status: active, not recruiting.
02
Drugs
belantamab mafodotindaratumumabbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2011210001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210001.